STEPS: Glycopyrrolate (Seebri Neohaler) for Maintenance Therapy in Patients with COPD

Glycopyrrolate (Seebri Neohaler) is an inhaled long-acting muscarinic antagonist agent labeled for maintenance treatment in patients diagnosed with chronic obstructive pulmonary disease (COPD).1-3 Drug Dosage Dose form Cost* Glycopyrrolate (Seebri Neohaler) 15.6 mcg inhaled twice a day 15.6-mcg capsule $419 *-Estimated retail price of one month's treatment based on information obtained at http://www.goodrx.com (accessed August 4, 2017). Some patients (less than 5%) reported experiencing mild dry mouth, upper respiratory tract infection (number needed to harm = 91), and nasopharyngitis (number needed to harm = 500).3,4 EFFECTIVENESS No long-term research has evaluated the effect of glycopyrrolate on mortality. Measures of quality of life have been shown to improve significantly for overall health, daily life, and perceived well-being in patients initiating maintenance treatment for moderate to severe COPD.4 In patients with severe to very severe airflow limitation (2008 GOLD class 3 or 4), glycopyrrolate and tiotropium (Spiriva) are similarly effective in preventing mild (i.e., managed at home) or moderate (i.e., requiring corticosteroid or antibiotic treatment) exacerbations.